China's WuXi XDC rises on robust results forecast

WuXi XDC Cayman

15/01/2025 02:37

** WuXi XDC Cayman  2268.HK  rises 4.4% to HK$30.75; set for
a second straight session of gains
    ** Chinese antibody drug developer sees 2024 rev, net profit
and adjusted net profit jumping more than 85%, 260% and 170%
y/y, respectively, on demand from antibody drug conjugate and
bioconjugate industries
    ** Profit margin improving on high utilisation rate of co's
production facilities; faster ramp-up of production lines also
increases operating efficiency
    ** Stock third biggest pct gainer on Hong Kong's healthcare
index  .HSCIH , which is down 0.7%

 (Reporting by Donny Kwok)
 ((donny.kwok@thomsonreuters.com))